Chen Qianping, Zheng Wang, Zhu Lin, Yao Dan, Wang Chen, Song Yimeng, Hu Songling, Liu Hongxia, Bai Yang, Pan Yan, Zhang Jianghong, Guan Jian, Shao Chunlin
Institute of Radiation Medicine, Shanghai Medical College, Fudan University, Shanghai, China.
Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Front Cell Dev Biol. 2020 Apr 16;8:232. doi: 10.3389/fcell.2020.00232. eCollection 2020.
Radiotherapy is a conventional and effective treatment method for nasopharyngeal carcinoma (NPC), although it can fail, mainly because radioresistance results in residual or recurrent tumors. However, the mechanisms and predictive markers of NPC radioresistance are still obscure. In this study, we identified Annexin A6 (ANXA6) as a candidate radioresistance marker by using Tandem Mass Tag quantitative proteomic analysis of NPC cells and gene chip analysis of NPC clinical samples with different radiosensitivities. It was observed that a high expression level of ANXA6 was positively correlated with radioresistance of NPC and that inhibition of ANXA6 by siRNA increased the radiosensitivity. The incidence of autophagy was enhanced in the established radioresistant NPC cells in comparison with their parent cells, and silencing autophagy with siRNA (siLC3) sensitized NPC cells to irradiation. Furthermore, siRNA (siANXA6) suppressed cellular autophagy by activating the PI3K/AKT/mTOR pathway, ultimately leading to radiosensitization. The combination of siANXA6 and CAL101 (an inhibitor of PI3K, p-AKT, and mTOR, concurrently) significantly reversed the above siANAX6-reduced autophagy. Suppression of PI3K/AKT/mTOR by CAL101 also increased the expression of ANXA6 in a negative feedback process. In conclusion, this study revealed for the first time that ANXA6 could promote autophagy by inhibiting the PI3K/AKT/mTOR pathway and that it thus contributes to radioresistance of NPC. The significance of this is that ANXA6 could be applied as a new predictive biomarker of NPC prognosis after radiotherapy.
放射治疗是鼻咽癌(NPC)的一种传统且有效的治疗方法,尽管它可能会失败,主要原因是放射抗性导致肿瘤残留或复发。然而,NPC放射抗性的机制和预测标志物仍不清楚。在本研究中,我们通过对NPC细胞进行串联质谱标签定量蛋白质组分析以及对具有不同放射敏感性的NPC临床样本进行基因芯片分析,将膜联蛋白A6(ANXA6)鉴定为候选放射抗性标志物。观察到ANXA6的高表达水平与NPC的放射抗性呈正相关,并且通过小干扰RNA(siRNA)抑制ANXA6可提高放射敏感性。与亲代细胞相比,在已建立的放射抗性NPC细胞中自噬发生率增加,并且用siRNA(siLC3)使自噬沉默可使NPC细胞对辐射敏感。此外,siRNA(siANXA6)通过激活PI3K/AKT/mTOR途径抑制细胞自噬,最终导致放射增敏。siANXA6与CAL101(一种同时抑制PI3K、p-AKT和mTOR的抑制剂)联合使用可显著逆转上述siANAX6降低的自噬。CAL101对PI3K/AKT/mTOR的抑制在负反馈过程中也增加了ANXA6的表达。总之,本研究首次揭示ANXA6可通过抑制PI3K/AKT/mTOR途径促进自噬,从而导致NPC的放射抗性。其意义在于ANXA6可作为放疗后NPC预后的一种新的预测生物标志物。